- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06803771
Surveillance de la santé pancréatique après le diagnostic du diabète (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: SAFE-D Trial Manager
- Numéro de téléphone: +442381205154
- E-mail: safed@soton.ac.uk
Lieux d'étude
-
-
-
Ashton-under-Lyne, Royaume-Uni, OL6 6HD
- Actif, ne recrute pas
- Ashton Medical Group
-
Birmingham, Royaume-Uni, B14 4DU
- Recrutement
- Yardley Wood Health Centre
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Bournemouth, Royaume-Uni, BH7 7DW
- Actif, ne recrute pas
- Bournemouth Research Hub
-
Bromborough, Royaume-Uni, CH62 6EE
- Recrutement
- Eastham Group Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Royaume-Uni, NW10 2PT
- Recrutement
- Willesden Medical Centre
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Royaume-Uni, SW1P 2PF
- Recrutement
- South Westminster Centre
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Royaume-Uni, W7 1DR
- Recrutement
- The Cuckoo Lane Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Manchester, Royaume-Uni, M14 6WP
- Actif, ne recrute pas
- Bodey Medical Centre
-
Manchester, Royaume-Uni, M23 1JX
- Actif, ne recrute pas
- Bowland Medical Practice
-
Manchester, Royaume-Uni, M23 2SY
- Actif, ne recrute pas
- The Maples Medical Centre
-
Nottingham, Royaume-Uni, NG17 4JL
- Recrutement
- King's Mill Hospital (Sherwood Forest) Research Van
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Portsmouth, Royaume-Uni, PO1 3HN
- Actif, ne recrute pas
- Portsmouth Research Hub
-
Rossendale, Royaume-Uni, BB4 5SL
- Recrutement
- Hazelvalley Family Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Ruislip, Royaume-Uni, HA4 8NX
- Recrutement
- Pembroke Centre (Hillingdon)
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Royaume-Uni, SO30 3JB
- Recrutement
- Moorgreen Hospital
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Royaume-Uni, SO15 33UA
- Actif, ne recrute pas
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Royaume-Uni, ST14 8JG
- Recrutement
- Balance Street Health Centre
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Uxbridge, Royaume-Uni, UB8 1UW
- Recrutement
- Civic Centre
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Walsall, Royaume-Uni, WS6 6EW
- Recrutement
- Quinton Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Weymouth, Royaume-Uni, DT4 0QE
- Actif, ne recrute pas
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Royaume-Uni, CW11 1EQ
- Actif, ne recrute pas
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Royaume-Uni, ME16 9QQ
- Recrutement
- Maidstone and Tunbridge Wells NHS Trust
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Royaume-Uni, LE3 3LW
- Recrutement
- Forest Medical Group
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Royaume-Uni, LE8 0LG
- Recrutement
- South Leicestershire Medical Group
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Royaume-Uni, DE14 3RH
- Recrutement
- Peel Croft Surgery
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Royaume-Uni, DY6 8DN
- Recrutement
- Kingswinford Medical Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Leek, Staffordshire, Royaume-Uni, ST13 6QR
- Recrutement
- Park Medical Centre
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Royaume-Uni, CV37 6HJ
- Recrutement
- Trinity Court Surgery
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Royaume-Uni, RH3 7NJ
- Recrutement
- Brockwood Medical Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Epsom, Surrey, Royaume-Uni, KT17 4BL
- Recrutement
- Integrated Care Partnership/ The Old Cottage Hospital
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
Warlingham, Surrey, Royaume-Uni, CR6 9NW
- Recrutement
- Warlingham Green Medical Practice
-
Contact:
- Anson-Wisniewska
- Numéro de téléphone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sensitivity of the Avantect test
Délai: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Délai: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Stage shift
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Délai: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time-to-event outcomes
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Délai: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Collaborateurs et enquêteurs
Collaborateurs
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Tumeurs par site
- Tumeurs
- Maladies métaboliques
- Tumeurs du système digestif
- Maladies du système digestif
- Troubles du métabolisme du glucose
- Tumeurs des glandes endocrines
- Maladies pancréatiques
- Maladies nutritionnelles et métaboliques
- Diabète sucré, Type 2
- Tumeurs pancréatiques
- Diabète sucré
- Cancer du pancréas, adulte
Autres numéros d'identification d'étude
- RHMGSU0292
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .